Brought to you by 
Knight gains Canadian and Israeli rights to TherapeuticsMD's TX004HR and TX001HR for menopausal symptoms
09 Aug 2018
Executive Summary
Knight Therapeutics Inc. licensed exclusive Canadian and Israeli commercialization rights to TherapeuticsMD Inc.'s hormone therapy candidates TX004HR (estradiol) and TX001HR (estradiol/progesterone) for menopausal symptoms.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Knight gains Canadian and Israeli rights to TherapeuticsMD's TX004HR and TX001HR for menopausal symptoms
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice